Gcore Enhances Everywhere Inference With Flexible Deployment Options, Including Cloud, On-Premise, and Hybrid
16.1.2025 10:01:00 CET | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced a major update to Everywhere Inference, formerly known as Inference at the Edge. This update offers greater flexibility in AI inference deployments, delivering ultra-low latency experiences for AI applications. Everywhere Inference now supports multiple deployment options including on-premise, Gcore's cloud, public clouds, or a hybrid mix of these environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250116487759/en/

Everywhere Inference leverages Gcore’s extensive global network of over 180 points of presence, enabling real-time processing, instant deployment, and seamless performance across the globe (Graphic: Business Wire)
Gcore developed this update to its inference solution to address changing customer needs. With AI inference workloads growing rapidly, Gcore aims to empower businesses with flexible deployment options tailored to their individual requirements. Everywhere Inference leverages Gcore’s extensive global network of over 180 points of presence, enabling real-time processing, instant deployment, and seamless performance across the globe. Businesses can now deploy AI inference workloads across diverse environments while ensuring ultra-low latency by processing workloads closer to end users. It also enhances cost management and simplifies regulatory compliance across regions, offering a comprehensive and adaptable approach to modern AI challenges.
Seva Vayner, Product Director of Edge Cloud and Edge AI at Gcore, commented: “The update to Everywhere Inference marks a significant milestone in our commitment to enhancing the AI inference experience and addressing evolving customer needs. The flexibility and scalability of Everywhere Inference make it an ideal solution for businesses of all sizes, from startups to large enterprises.”
The new update enhances deployment flexibility by introducing smart routing, which automatically directs workloads to the nearest available compute resource. Additionally, Everywhere Inference now offers multi-tenancy for AI workloads, leveraging Gcore’s unique multi-tenancy capabilities to run multiple inference tasks simultaneously on existing infrastructure. This approach optimizes resource utilization for greater efficiency.
These new features address common challenges faced by businesses deploying AI inference. Balancing multiple cloud providers and on-premises systems for operations and compliance can be complex. The introduction of smart routing enables users to direct workloads to their preferred region, helping them stay compliant with local data regulations and industry standards. Data security is another key concern and with Gcore’s new flexible deployment options, businesses can securely isolate sensitive information on-premise, enhancing data protection.
Learn more at https://gcore.com/everywhere-inference.
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, with a team of 600 operating from ten offices worldwide, Gcore provides solutions to global leaders in numerous industries. Gcore manages its global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM due to the average response time of 30 ms worldwide. Gcore’s network consists of 180 points of presence worldwide in reliable Tier IV and Tier III data centers, with a total network capacity exceeding 200 Tbps. Learn more at gcore.com and follow them on LinkedIn, Twitter, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116487759/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom